Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 141 (7-8), 807-16

Clinical and Field Trials With Attenuated Salmonella Typhi as Live Oral Vaccines and as "Carrier" Vaccines

Affiliations
Review

Clinical and Field Trials With Attenuated Salmonella Typhi as Live Oral Vaccines and as "Carrier" Vaccines

M M Levine et al. Res Microbiol.

Abstract

In recent years there has been a resurgence of research to develop new and improved attenuated strains of Salmonella typhi to function as live oral vaccines against typhoid fever and to serve as "carrier" vaccines to express foreign antigens of other pathogens and deliver them to the immune system. Strain Ty21a has served as a prototype in clinical and field trials to identify the optimal formulations and dosage schedules for live vaccines and to quantitate the duration of protection that can be achieved. Clinical trials with three new attenuated S. typhi candidate vaccines, a Vi+ variant of Ty21a, an aroC,aroD double mutant recombinant strain and a cya,crp double mutant, are underway or will be initiated shortly.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback